☆ 4.7 Article

Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study

TRANSLATIONAL PSYCHIATRY (2022)

Journal

TRANSLATIONAL PSYCHIATRY

Volume 12, Issue 1, Pages -

Publisher

SPRINGERNATURE

DOI: 10.1038/s41398-022-02124-4

Keywords

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Automated Summary New
Abstract

Cytochrome P450 drug-metabolizing enzymes, specifically CYP2C19 and CYP2D6 gene variants, have an impact on antidepressant outcomes. Poor metabolizers of CYP2C19 and CYP2D6 show less symptom improvement during treatment with escitalopram alone and are more likely to experience central nervous system side effects when taking escitalopram alone or in combination with aripiprazole.

Cytochrome P450 drug-metabolizing enzymes may contribute to interindividual differences in antidepressant outcomes. We investigated the effects of CYP2C19 and CYP2D6 gene variants on response, tolerability, and serum concentrations. Patients (N=178) were treated with escitalopram (ESC) from weeks 0-8 (Phase I), and at week 8, either continued ESC if they were responders or were augmented with aripiprazole (ARI) if they were non-responders (<50% reduction in Montgomery-angstrom sberg Depression Rating Scale from baseline) for weeks 8-16 (Phase II). Our results showed that amongst patients on ESC-Only, CYP2C19 intermediate and poor metabolizers (IM + PMs), with reduced or null enzyme function, trended towards significantly lower symptom improvement during Phase II compared to normal metabolizers (NMs), which was not observed in ESC + ARI. We further showed that CYP2D6 NMs and IM + PMs had a higher likelihood of reporting a treatment-related central nervous system side effect in ESC-Only and ESC + ARI, respectively. The differences in the findings between ESC-Only and ESC + ARI may be due to the altered pharmacokinetics of ESC by ARI coadministration in ESC + ARI. We provided evidence for this postulation when we showed that in ESC-Only, CYP2C19 and CYP2D6 IM + PMs demonstrated significantly higher ESC concentrations at Weeks 10 and 16 compared to NMs. In contrast, ESC + ARI showed an association with CYP2C19 but not with CYP2D6 metabolizer group. Instead, ESC + ARI showed an association between CYP2D6 metabolizer group and ARI metabolite-to-drug ratio suggesting potential competition between ESC and ARI for CYP2D6. Our findings suggest that dosing based on CYP2C19 and CYP2D6 genotyping could improve safety and outcome in patients on ESC monotherapy.

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

Significance

Scientific rigor

Rate this paper

Influence of CYP2C19, CYP2D6, and ABCB1 Gene Variants and Serum Levels of Escitalopram and Aripiprazole on Treatment-Emergent Sexual Dysfunction: A Canadian Biomarker Integration Network in Depression 1 (CAN-BIND 1) Study

Farhana Islam, Leen Magarbeh, Samar S. M. Elsheikh, Stefan Kloiber, Caroline W. Espinola, Venkat Bhat, Benicio N. Frey, Roumen Milev, Claudio N. Soares, Sagar V. Parikh, Franca Placenza, Stefanie Hassel, Valerie H. Taylor, Francesco Leri, Pierre Blier, Rudolf Uher, Faranak Farzan, Raymond W. Lam, Gustavo Turecki, Jane A. Foster, Susan Rotzinger, Sidney H. Kennedy, Daniel J. Mueller

Summary: Treatment-emergent sexual dysfunction is a common issue in individuals with major depressive disorder on antidepressants. This study found that polymorphisms in genes encoding drug-metabolizing enzymes and the transmembrane efflux pump were associated with changes in sexual function and satisfaction. Specifically, CYP2C19 metabolizer phenotypes were linked to changes in sexual arousal, and higher concentrations of the escitalopram metabolite, S-desmethylcitalopram, were associated with a decline in sexual function and satisfaction in females.

CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2023)